$ENSC
Ensysce Biosciences, Inc. Stock $ensc

$ensc Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032094 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$1.433M	$279.4K	$1.201M
YoY Change	-12.34%	-76.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.192M	$1.687M	$16.37M
YoY Change	-18.01%	-89.7%
% of Gross Profit
Research & Development	$6.442M	$4.756M	$1.715M
YoY Change	194.44%	177.38%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$50.00
YoY Change		-100.0%
% of Gross Profit
Operating Expenses	$7.634M	$6.443M	$18.09M
YoY Change	109.61%	-64.38%	6196.82%
Operating Profit		-$6.163M	-$16.89M
YoY Change		-63.5%
Interest Expense	-$51.86K	$4.859K	-$1.350M
YoY Change	-102.61%	-100.36%	-73494.57%
% of Operating Profit
Other Income/Expense, Net	$739.1K	-$3.692M	$1.038M
YoY Change	-107.13%	-455.78%
Pretax Income	-$5.478M	-$9.856M	-$17.20M
YoY Change	-45.42%	-42.7%	5926.23%
Income Tax
% Of Pretax Income
Net Earnings	-$5.522M	-$9.856M	-$17.16M
YoY Change	-44.98%	-42.58%	-7943.68%
Net Earnings / Revenue	-385.22%	-3528.02%	-1429.32%
Basic Earnings Per Share		-$5.13	-$14.15
Diluted Earnings Per Share	-$18.21	-$5.099M	-$707.6K
COMMON SHARES
Basic Shares Outstanding	2.841M shares	37.32M shares	1.213M shares
Diluted Shares Outstanding		160.7K shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.148M	$4.503M	$6.846M
YoY Change	-74.34%	-34.22%	12698.04%
Cash & Equivalents	$3.148M	$4.503M	$6.846M
Short-Term Investments
Other Short-Term Assets	$1.875M	$3.018M	$1.989M
YoY Change	-36.58%	51.77%	4014.98%
Inventory
Prepaid Expenses	$1.847M	$2.983M
Receivables	$276.8K	$140.8K	$86.87K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.299M	$7.662M	$8.921M
YoY Change	-66.17%	-14.11%	8661.84%
LONG-TERM ASSETS
Property, Plant & Equipment			$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$585.9K	$627.6K	$796.4K
YoY Change	-22.37%	-21.2%	-93.96%
Total Long-Term Assets	$585.9K	$627.6K	$796.4K
YoY Change	-22.37%	-21.2%	-93.96%
TOTAL ASSETS
Total Short-Term Assets	$5.299M	$7.662M	$8.921M
Total Long-Term Assets	$585.9K	$627.6K	$796.4K
Total Assets	$5.885M	$8.290M	$9.718M
YoY Change	-64.15%	-14.69%	-26.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.944M	$1.286M	$471.9K
YoY Change	877.67%	172.44%	44.55%
Accrued Expenses	$2.254M	$2.272M	$3.762M
YoY Change	-34.34%	-39.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.267M	$7.553M	$2.797M
YoY Change	-66.53%	170.01%
Total Short-Term Liabilities	$9.464M	$11.91M	$7.031M
YoY Change	-42.58%	69.38%	1455.29%
LONG-TERM LIABILITIES
Long-Term Debt	$140.2K	$1.387M	$2.114M
YoY Change	-96.84%	-34.41%	273.4%
Other Long-Term Liabilities	$310.3K	$1.415M	$957.1K
YoY Change	-91.5%	47.82%	-86.33%
Total Long-Term Liabilities	$450.5K	$2.802M	$3.072M
YoY Change	-87.67%	-8.78%	-59.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.464M	$11.91M	$7.031M
Total Long-Term Liabilities	$450.5K	$2.802M	$3.072M
Total Liabilities	$9.915M	$14.71M	$9.823M
YoY Change	-59.66%	49.76%	22.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.9M	-$105.4M
YoY Change	29.19%
Common Stock	$642.00	$221.00
YoY Change	-73.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.714M	-$6.094M	-$105.7K
YoY Change
Total Liabilities & Shareholders Equity	$5.885M	$8.290M	$9.718M
YoY Change	-64.15%	-14.69%	-26.88%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$5.522M	-$9.856M	-$17.16M
YoY Change	-44.98%	-42.58%	-7943.68%
Depreciation, Depletion And Amortization	$0.00	$0.00	$50.00
YoY Change		-100.0%
Cash From Operating Activities	-$3.296M	-$6.714M	-$3.825M
YoY Change	-12.53%	75.54%	3364.9%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$1.178M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.940M	7.483M	2.659M
YoY Change	-78.88%	181.43%
NET CHANGE
Cash From Operating Activities	-3.296M	-6.714M	-3.825M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	1.940M	7.483M	2.659M
Net Change In Cash	-1.355M	768.4K	-1.166M
YoY Change	-125.01%	-165.9%	1556.64%
FREE CASH FLOW
Cash From Operating Activities	-$3.296M	-$6.714M	-$3.825M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001716947
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021Q3	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes		usd
	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes		usd
CY2021Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount		usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount		usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q3	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
	us-gaap	Depreciation Depreciation		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Accretion Expense AccretionExpense		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	ENSC	Change In Fair Value Of Liabilities Classified Warrants ChangeInFairValueOfLiabilitiesClassifiedWarrants		usd
	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	ENSC	Commitment Fee For Share Subscription Facility CommitmentFeeForShareSubscriptionFacility		usd
	ENSC	Warrant Modification WarrantModification		usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
	ENSC	Stockbased Compensation StockbasedCompensation		usd
	ENSC	Payable To Related Parties PayableToRelatedParties		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
	ENSC	Share Subscription Facility Transaction Costs ShareSubscriptionFacilityTransactionCosts		usd
	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision		usd
CY2022Q3	us-gaap	Depreciation Depreciation		usd
	us-gaap	Depreciation Depreciation		usd
CY2022Q3	ENSC	Consultant Stock Compensation Expenses ConsultantStockCompensationExpenses		usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
	ENSC	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38306
	dei	Entity Registrant Name EntityRegistrantName	Ensysce Biosciences, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2755287
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7946 Ivanhoe Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201
	dei	Entity Address City Or Town EntityAddressCityOrTown	La Jolla
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92037
	dei	City Area Code CityAreaCode	(858)
	dei	Local Phone Number LocalPhoneNumber	263-4196
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Bankruptcy Proceedings Reporting Current EntityBankruptcyProceedingsReportingCurrent	true
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2841091	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4503081	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12264736	usd
CY2022Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	140813	usd
CY2021Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	441721	usd
CY2022Q3	ENSC	Operating Lease Right Of Use Current Asset OperatingLeaseRightOfUseCurrentAsset	35313	usd
CY2021Q4	ENSC	Operating Lease Right Of Use Current Asset OperatingLeaseRightOfUseCurrentAsset	24721	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2983071	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2931415	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	7662278	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	15662593	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	627550	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	754756	usd
CY2022Q3	us-gaap	Assets Assets	8289828	usd
CY2021Q4	us-gaap	Assets Assets	16417349	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1285514	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	301104	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2236273	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3407533	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	800000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35403	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24874	usd
CY2022Q3	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	7199135	usd
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	12358886	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	7552774	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	12748155	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11909964	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16481666	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	1386967	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4440951	usd
CY2022Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	1414829	usd
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	3652790	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2801796	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8093741	usd
CY2022Q3	us-gaap	Liabilities Liabilities	14711760	usd
CY2021Q4	us-gaap	Liabilities Liabilities	24575407	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2208446	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1233148	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2207458	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1232160	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	221	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	124	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	99314436	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	77967200	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105409155	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85845567	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6094498	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7878243	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-327434	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-279815	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6421932	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8289828	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16417349	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	279351	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1200816	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1089920	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1895907	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4756096	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1714635	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13393948	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2502232	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1686580	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16372976	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5717281	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17257361	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	6442676	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	18087611	usd
	us-gaap	Operating Expenses OperatingExpenses	19111229	usd
	us-gaap	Operating Expenses OperatingExpenses	19759593	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6163325	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16886795	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18021309	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17863686	usd
CY2022Q3	ENSC	Issuance Costs For Convertible Notes IssuanceCostsForConvertibleNotes	1118721	usd
CY2021Q3	ENSC	Issuance Costs For Convertible Notes IssuanceCostsForConvertibleNotes	500158	usd
	ENSC	Issuance Costs For Convertible Notes IssuanceCostsForConvertibleNotes	1118721	usd
	ENSC	Issuance Costs For Convertible Notes IssuanceCostsForConvertibleNotes	500158	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	673314	usd
CY2022Q3	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes	-3609944	usd
	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes	-3609944	usd
CY2022Q3	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-3491513	usd
CY2021Q3	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-1071099	usd
	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-6169929	usd
	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-1071099	usd
CY2022Q3	ENSC	Issuance Of Liability Classified Warrants IssuanceOfLiabilityClassifiedWarrants	3737371	usd
CY2021Q3	ENSC	Issuance Of Liability Classified Warrants IssuanceOfLiabilityClassifiedWarrants	1325804	usd
	ENSC	Issuance Of Liability Classified Warrants IssuanceOfLiabilityClassifiedWarrants	3737371	usd
	ENSC	Issuance Of Liability Classified Warrants IssuanceOfLiabilityClassifiedWarrants	1325804	usd
CY2022Q3	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	2683340	usd
CY2021Q3	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	405086	usd
	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	5626130	usd
	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	405086	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	4000155	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	4859	usd
CY2022Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1404877	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	24660	usd
	us-gaap	Interest Expense InterestExpense	57662	usd
	us-gaap	Interest Expense InterestExpense	1282820	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-347566	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8679	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61758	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19494	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61758	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3692240	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-312679	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-708300	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1245091	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-9855565	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-17199474	usd
	us-gaap	Profit Loss ProfitLoss	-18729609	usd
	us-gaap	Profit Loss ProfitLoss	-19108777	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-21492	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-35948	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-47619	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-61976	usd
CY2022Q3	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	63539	usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	881598	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9897612	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17163526	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19563588	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19046801	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.13
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-20.31
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1928727	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1212791	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1666253	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	937764	shares
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5167292	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24833	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11565472	usd
CY2021Q3	ENSC	Adjustments To Additional Paid In Capital Warrants Modification AdjustmentsToAdditionalPaidInCapitalWarrantsModification	56590	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-17199474	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-385287	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-797578	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4074063	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	157148	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-9855565	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6421932	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6658427	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	262862	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5696703	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	7695264	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	105026	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11565472	usd
	ENSC	Adjustments To Additional Paid In Capital Warrants Modification AdjustmentsToAdditionalPaidInCapitalWarrantsModification	56590	usd
	us-gaap	Profit Loss ProfitLoss	-19108777	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-385287	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	54250	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	17868097	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2543388	usd
	us-gaap	Profit Loss ProfitLoss	-18729609	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6421932	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6421932	usd
	us-gaap	Profit Loss ProfitLoss	-18729609	usd
	us-gaap	Profit Loss ProfitLoss	-19108777	usd
	us-gaap	Depreciation Depreciation	151	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4500	usd
	ENSC	Accrued Interest AccruedInterest	57536	usd
	ENSC	Accrued Interest AccruedInterest	336851	usd
	us-gaap	Accretion Expense AccretionExpense	945969	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	673314	usd
	ENSC	Change In Fair Value Of Liabilities Classified Warrants ChangeInFairValueOfLiabilitiesClassifiedWarrants	5626130	usd
	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes	-3609944	usd
	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-6169929	usd
	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-1071099	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-347566	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	855160	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	105026	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11565472	usd
	ENSC	Issuance Of Liabilities Classified Warrants IssuanceOfLiabilitiesClassifiedWarrants	3737371	usd
	ENSC	Issuance Of Liabilities Classified Warrants IssuanceOfLiabilitiesClassifiedWarrants	620718	usd
	ENSC	Adjustments Issuance Costs For Convertible Notes AdjustmentsIssuanceCostsForConvertibleNotes	946085	usd
	ENSC	Adjustments Issuance Costs For Convertible Notes AdjustmentsIssuanceCostsForConvertibleNotes	800158	usd
	ENSC	Commitment Fee For Share Subscription Facility CommitmentFeeForShareSubscriptionFacility	1124292	usd
	ENSC	Warrant Modification WarrantModification	-56590	usd
	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-63	usd
	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-1838	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	4000155	usd
	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	-300908	usd
	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	86867	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-475499	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	683492	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	984410	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1252740	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	971344	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2500970	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14591819	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4474364	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4500	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4500	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7533915	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4549842	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	350000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	262862	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	467774	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	265812	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6626312	usd
	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	442439	usd
	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	195420	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6825664	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11125822	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7761655	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6651458	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12264736	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194214	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4503081	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6845672	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
	ENSC	Stockbased Compensation StockbasedCompensation	1742478	usd
	ENSC	Conversions Of Convertible Notes And Accrued Interest Into Common Stock ConversionsOfConvertibleNotesAndAccruedInterestIntoCommonStock	13879535	usd
	ENSC	Conversions Of Convertible Notes And Accrued Interest Into Common Stock ConversionsOfConvertibleNotesAndAccruedInterestIntoCommonStock	5696703	usd
	ENSC	Payable To Related Parties PayableToRelatedParties	800000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	1068950	usd
	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	399949	usd
	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	867300	usd
	ENSC	Share Subscription Facility Transaction Costs ShareSubscriptionFacilityTransactionCosts	12689764	usd
	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	881598	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_801_eus-gaap--BasisOfAccounting_zvQ2en7vYAXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_822_zZa1e3qdKLf1">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three and nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2021, which may be found in the Company’s Form 10-K filed with the SEC on March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2022, the Company completed a <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20221027__20221028__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVn4fgsMK00h" title="Reverse stock split">1-for-20 reverse split </span>of its outstanding common stock. All references in these consolidated financial statements to shares and per share amounts in all periods have been retroactively restated to reflect the split (see Note 11).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Combination</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $<span id="xdx_90A_eus-gaap--Cash_iI_pn5n6_c20220930_zIlH8AxaUcbg" title="Cash">7.8</span> million and prepaid expenses of $<span id="xdx_909_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn5n6_c20220930_z1SoKyUJFxT4" title="Prepaid expense">1.1</span> million, were recorded at historical cost with no goodwill or other intangible assets recorded. The shares and net loss per share prior to the reverse recapitalization have been retroactively restated to reflect the exchange ratio of <span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220930_zbpl5JKGlhIh" title="Debt Instrument, conversion price">0.06585</span>. The financial statements reflect the historical operations of Ensysce.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not generated any product revenue and had an accumulated deficit of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220930_zxTiDyabVaMa" title="Accumulated deficit">105.4</span> million at September 30, 2022. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company executed the GEM Agreement. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $<span id="xdx_901_eus-gaap--CommonStockSharesSubscriptions_iI_pn5n6_c20201231_z4kbMtfGuUhh" title="Common stock, subscriptions value">60.0</span> million for a 36-month term following the public listing of the Company’s common stock. The Company controls the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. On June 30, 2021, the Company consummated the Business Combination, resulting in the Company’s shares becoming publicly listed on Nasdaq on July 2, 2021. Concurrent with the public listing of the Company’s shares, the Company issued to the investor <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zTvsEawIiZyg" title="Warrants issued shares">55,306</span> warrants with a five-year term to purchase common stock of Ensysce at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zmmAq6WkOYtd" title="Warrant, exercise price">200.20</span> per share (Note 8). The Company is required to pay a commitment fee to the investor of $<span id="xdx_90C_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zPn1K1V6CRMf" title="Commitment fees">1.2</span> million with $<span id="xdx_908_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--FirstAnniversaryMember_zzxrlQjntA42" title="Commitment fees">0.8 million</span> due on the first anniversary of the public listing date and $<span id="xdx_90C_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--EighteenMonthAnniversaryMember_z6Zj675BAUL6" title="Commitment fees">0.4 million</span> due on the 18-month anniversary of the public listing date. The first $<span id="xdx_908_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20220701__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JulyTwentyTwentyTwoMember_zfRy6ijzn2wf" title="Commitment fees">0.8 million</span> of the commitment fee was paid in July 2022 in common stock of the Company (Note 10) and the remaining $<span id="xdx_90B_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20220701__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyThreeMember_zKSdJYJMrWF5" title="Commitment fees">0.4 million</span> due in January 2023 may be paid from the proceeds of a draw against the facility or in freely tradable common stock of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2021, the Company entered into a $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20210930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteFinancingAgreementMember_zhL0VMB4pmKk" title="Debt instrument, face amount">15.9</span> million convertible note financing agreement with institutional investors (the “2021 Notes”) (See Note 7 for additional information). In July and August 2022, the Company received funding under a $<span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_pn4n6_c20220801__20220809_zTXMQ8qrYkW8" title="Proceeds from issuance of convertible notes">8.48</span> million convertible note financing agreement with the same institutional investors (the “2022 Notes”) (Note 7). The agreements limit the Company’s ability to execute certain debt and equity financings, including under the GEM Agreement, while the convertible notes are outstanding. Without the availability of proceeds through the GEM Agreement, existing cash resources are not sufficient to fund current planned operations. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Cash Cash	7800000	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1100000	usd
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.06585
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105400000	usd
CY2020Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	60000000.0	usd
CY2022Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	8480000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zcpjzRqVeVb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zXuqhpXss1ce">Use of Estimates and Assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, warrants, options to purchase the Company’s common stock, and the notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zuDAQpvluU63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zSdwW14rVexb">Concentrations of credit risk and off-balance sheet risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q3	us-gaap	Depreciation Depreciation	50	usd
	us-gaap	Depreciation Depreciation	151	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	15900000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	8500000	usd
CY2022Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	8586102	usd
CY2022Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1414829	usd
CY2022Q3	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	10000931	usd
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	16799837	usd
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	3303588	usd
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	20103425	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20103425	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	12217371	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	-14133750	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-8186115	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10000931	usd
CY2018Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5100000	usd
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	10800000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2021Q4	ENSC	Consultant Stock Compensation Expenses ConsultantStockCompensationExpenses	1342479	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	89485	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	67939	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	279351	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1200816	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1089920	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1895907	usd
CY2022Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	214308	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9897612	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17163526	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19563588	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19046801	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1928727	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1212791	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1666253	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	937764	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.13
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-20.31
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1405539	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1223156	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1383082	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	561364	shares
CY2021Q4	ENSC	Accrued Scientific Advisory Board Fees AccruedScientificAdvisoryBoardFees	60032	usd
CY2022Q3	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	2323473	usd
CY2021Q4	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	2124008	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	550634	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	733234	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	108964	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	74173	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2983071	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2931415	usd
CY2022Q3	ENSC	Share Subscription Facility Commitments Fees ShareSubscriptionFacilityCommitmentsFees	400000	usd
CY2021Q4	ENSC	Share Subscription Facility Commitments Fees ShareSubscriptionFacilityCommitmentsFees	800000	usd
CY2022Q3	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	1186498	usd
CY2021Q4	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	388997	usd
CY2022Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	297224	usd
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	610000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	203034	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	138086	usd
CY2022Q3	ENSC	Accrued Scientific Advisory Board Fees AccruedScientificAdvisoryBoardFees	60032	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2236273	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3407533	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1414829	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3652790	usd
CY2022Q3	us-gaap	Contractual Obligation ContractualObligation	25700000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	35403	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	7939	usd
	us-gaap	Payments For Rent PaymentsForRent	23606	usd
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	11781	usd
	us-gaap	Payments For Rent PaymentsForRent	36058	usd
CY2021Q4	ENSC	Consultant Stock Compensation Expenses ConsultantStockCompensationExpenses	1342479	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	8855142	usd
CY2022Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	109424	usd
CY2022Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	24825	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	8939741	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	14032528	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	163517	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2993061	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	17189106	usd
CY2022Q3	ENSC	Stated Interest Accrual StatedInterestAccrual	4859	usd
CY2021Q3	ENSC	Stated Interest Accrual StatedInterestAccrual	24660	usd
	ENSC	Stated Interest Accrual StatedInterestAccrual	6864	usd
	ENSC	Stated Interest Accrual StatedInterestAccrual	251857	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	945969	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	4859	usd
CY2021Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	24660	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	6864	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1197826	usd
CY2022Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	100000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	100000	usd
CY2021	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	900000	usd
	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	400000	usd
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	310963	shares
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	67899	shares
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5800000	usd
CY2021Q1	ENSC	Termination Of Common Stock Issued TerminationOfCommonStockIssued	25000	shares
CY2021Q2	ENSC	Deferred Underwriting Common Stock Issued DeferredUnderwritingCommonStockIssued	6250	shares
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	945063	shares
CY2021Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-06-30
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	55306	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	90.00
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	56.60
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	31.60
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	19.20
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	18.80
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.20
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.00
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.00
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.60
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.00
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	18058	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	152.60
CY2021Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-09-23
CY2022Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2027-08-08
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	36116	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	152.60
CY2021Q4	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-11-04
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	233394	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.17
CY2022Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2027-06-29
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	233394	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.17
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	222191	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	48.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10207306	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	114550	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	77.30
	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Grants SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGrants	P7Y7M17D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	10000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	21.40
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	326741	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	59.13
	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y6M25D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	284014	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	62.03
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	326741	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	59.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y6M25D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7661	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9587	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0152	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0314	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	19.24
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	605868	usd
	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Period Expected To Be Recognized SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized	P1Y5M1D
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2662816	shares

Files In Submission

Name	View Source	Status
0001493152-22-032094-index-headers.html	Edgar Link	pending
0001493152-22-032094-index.html	Edgar Link	pending
0001493152-22-032094.txt	Edgar Link	pending
0001493152-22-032094-xbrl.zip	Edgar Link	pending
ensc-20220930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
ensc-20220930_def.xml	Edgar Link	unprocessable
ensc-20220930_lab.xml	Edgar Link	unprocessable
ensc-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ensc-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENSC
Ensysce Biosciences, Inc. Stock $ensc

2022 Q4 Form 10-Q Financial Statement

#000149315222032094 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC Ensysce Biosciences, Inc. Stock $ensc

2022 Q4 Form 10-Q Financial Statement

#000149315222032094 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC
Ensysce Biosciences, Inc. Stock $ensc